Consistent with our finding, the INtravenous Thrombolysis REgistry for Chinese Ischaemic Stroke (INTRECIS) registry showed a trend favoring the standard dose among patients aged ≥65 years (OR = 1.04 for excellent functional outcome, 95% CI 0.57–1.87) compared to those aged <65 years (OR = 2.69, 95% CI 1.22–6.75), although no significant interaction between the alteplase dose and age (<65 vs. ≥65 years, P interaction = 0.06) was observed ( 27 ).
← all excerpts
Low-dose vs. standard-dose intravenous alteplase for acute ischemic stroke with unknown time of onset.
1
—
—